Advancing the management of cow’s milk protein allergy: from research to clinical practice

Professor Nowak-Wegrzyn highlights how HMO research has progressively shown benefits in healthy infants and those with cow’s milk protein allergy (CMPA), specifically relating to two key HMO: 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT). These studies demonstrated the safety and efficacy of the novel hypoallergenic whey-based EHF with HMO in infants with CMPA and showed an important benefit of reducing the frequency of upper respiratory tract infections. In addition, she highlights how 2’FL and LNnT positively modulate gut microbiota composition.